What dosing range for MTX do you typically use for treating SCC in situ on the trunk and extremities?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

Should JAK inhibitors be avoided in patients with a recent history of melanoma?

How do you approach biopsy and management decisions for a rapidly enlarging periocular tumor in an elderly patient with dementia who is unable to communicate and whose family prefers to avoid aggressive treatment?

Have you noticed increased incidence of skin cancers for solid-organ transplant patients on CTLA4 inhibitors (ie: belatacept)?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.